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Prognostic value of inducible myocardial ischemia in predicting
cardiovascular events after renal transplantation.
Background. The aims of the present study were to determine
the prevalence of inducible myocardial ischemia (IMI) in renal
transplant recipients (RTR) more than 50 years old, to identify
predictors of IMI, and to search for its prognostic value.
Methods. Among the 377 renal transplantations performed
between 1989 and 1998 in a single institution, 120 were done
in patients ≥50 years old, and 97 were recruited for the study.
During the last quarter of 1998, all of them underwent an exer-
cise test (EST), an exercise-thallium 201 single photon emission
computed tomography coupled with dipyridamole (SPECT),
and 81% of them had a dobutamine stress echocardiography
(DSE). Patients with IMI subsequently underwent coronary an-
giography to detect coronary stenosis.
Results. IMI was present in 12 of the 97 patients (10%). The
diagnosis was evidenced by EST in four cases, by SPECT in 11
cases, and DSE in three cases. Five of these 12 patients (42%)
had significant coronary artery stenosis (≥50%). Multivariate
analysis of several pre- and post-transplant variables evidenced
acute rejection and left ventricular hypertrophy as significant
correlates of IMI (both P < 0.03). Patients were prospectively
followed-up for 48 months for the occurrence of major cardio-
vascular events. Kaplan-Meier analysis revealed a significant in-
crease in cardiovascular events in the IMI group (P < 0.0001).
In addition, the Cox proportional hazards model revealed that
IMI and diabetes mellitus had an independent significant effect
on the occurrence of major cardiovascular events.
Conclusion. IMI was present in 10% of RTR aged ≥50 years,
and was predicted by acute rejection and left ventricular hyper-
trophy. IMI had a strong effect on major cardiovascular events
in this population.
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Cardiovascular disease (CVD) is the leading cause of
death in renal transplant recipients (RTR) [1, 2]. Death
due to cardiovascular disease with a functional trans-
plant is the first cause of transplant loss [3, 4]. It not
only accounts for the increased mortality of these pa-
tients, but it is also a major cause of morbidity [5]. The
high incidence of cardiovascular events in RTR is asso-
ciated with an increased prevalence of traditional risk
factors, such as diabetes, hypertension, and dyslipidemia
[6–9]. Hyperhomocysteinemia and renal failure are also
involved [10–12]. Finally, factors directly linked to the
transplantation also play significant roles, such as toxic ef-
fects of immunosuppression [13], rejection, and infections
[14, 15].
Coronary artery disease is the main cause of myocar-
dial ischemia in RTR [16], and coronary angiography is
still the gold standard for assessing the diagnosis. But
this procedure is invasive and costly. Actually, to detect
myocardial ischemia, most centers rely on noninvasive
cardiac stress testing, usually performed before the trans-
plantation [17]. Moreover, in 30% of RTR, myocardial
ischemia is not related to a significant stenosis of the coro-
nary artery and may be due to a microangiopathy in rela-
tion with diabetes, left ventricular hypertrophy, calcium
deposits, and endothelial dysfunction [18].
Cohn [19] has estimated that up to 4% of apparently
healthy asymptomatic middle-aged men have inducible
myocardial ischemia (IMI). In asymptomatic men with
two or more major coronary risk factors, the prevalence
reaches 10% [20, 21]. The prevalence is from 15% to 30%
in patients with previous myocardial infarction [22]. In
hemodialyzed patients, the prevalence increases to 40%
[23].
The aims of this study were to determine the prevalence
of IMI in a large group of RTR over 50 years of age. In
addition, we looked for correlates for IMI. After testing,
patients were followed-up for four years to determine
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377 cadaveric kidney
transplantations in 374 
patients between Nov 1988
and Aug 1998 (374 patients
had one graft, 3 had
two grafts)
162 RTR
aged ≥50 years
Death N = 24
Transplant loss N = 18
(before September 1998)
120 RTR were alive with
a functional transplant
in September 1998
97 RTR performed
the study
N = 23 (ECG abnormalities
interfering with ST segment, lost
for follow-up, patient's refusal)
Fig. 1. Profile of the study.
the incidence of cardiovascular events in patients with or
without IMI.
METHODS
Study population
We analyzed the records of all cadaveric kidney trans-
plantations (N = 377) performed between November
1988 and August 1998 in a single center. Since 1988, all
patient data have been recorded on a microcomputer
with a specific database management program. Among
the 374 renal transplants recipients, 162 were ≥50 years
old. At the time of the study, 120 patients were alive with
a functional transplant. Twenty-three patients were ex-
cluded from the study either because of ECG abnormal-
ities interfering with exercise ST-segment interpretation
(major left ventricular hypertrophy, left bundle branch
block, pre-excitation, atrial fibrillation) or because they
declined to participate in the study or were lost to
follow-up. Thus, 97 patients performed the study (Fig. 1).
The characteristics of the patients who did not partici-
pate did not differ from those in the study population
(data not shown). None of the patients had suffered from
myocardial infarction or undergone bypass surgery or
percutaneous revascularization during the previous year.
Ten patients had previous coronary artery disease two
or more years before the start of the study. Among
these 10 patients, two had myocardial infarction and eight
had acute coronary syndrome necessitating percutaneous
revascularization. All patients gave their informed con-
sent to participate in the study.
All the patients were treated by hemodialysis before
transplantation. After transplantation, they all received
the same quadruple sequential therapy with thymoglobu-
lins 1 amp/10 kg/day (Thymoglobulins; Institut Me´rieux,
France) for seven days, prednisone 1 mg/kg/day tapered
to 0.25 mg/kg/day from D15 to D30, and azathioprine
3 mg/kg/day secondarily adjusted to white cell count. Cy-
closporine (6 mg/kg/day) was started at D5. The target
whole blood levels were 200 to 300 ng/mL during the
first three months and then 150 to 250 ng/mL afterwards.
During the follow up, immunosuppressive treatments
were modified according to clinical events. The diagno-
sis of acute rejection was based on standard clinical and
pathologic criteria [24]. Antirejection therapy was either
methylprednisolone pulses or monoclonal antibodies to
CD3, according to the severity of the rejection.
Detection of inducible myocardial ischemia and
coronary angiography
Before IMI detection, patients underwent a clinical
screening that included a detailed history and a resting
electrocardiography. Detection tests were performed af-
ter complete discontinuation of medications that have
potential antianginal effects: two days for b-blockers, and
one to three days for calcium-channel blockers. Screen-
ing tests and coronarographies were performed by the
same cardiologist (B.S. for exercise test, B.S. and O.M.
for scintigraphy, G.H. for dobutamine stress echocardio-
graphy, J.L.B. for coronarography). All the patients were
referred to exercise test and scintigraphy. Dobutamine
echocardiography was optional but recommended, and
coronarography was indicated in case of IMI detection.
Exercise test (EST)
Exercise electrocardiography was performed on a cy-
cloergometer through a protocol starting at a workload
of 30 watts, with increments of 30 watts every 3 minutes
and a 12-lead ECG analysis system (Marquette CASE
16; Marquette Electronics, Milwaukee, WI, USA). The
criteria for interruption of exercise were fatigue, chest
pain, dyspnea, decreased systolic blood pressure, exer-
tional blood pressure above 250/120 mm Hg, congestive
heart failure, and severe ventricular or supraventricular
arrythmias. The test was considered negative if no sig-
nificant ECG abnormalities were observed upon reach-
ing or exceeding at least 85% of the maximal predicted
heart rate as calculated by the Astrand formula (220-
age). The test was considered positive when horizontal
or downsloping ST-segment depression ≥1 mm was ob-
served 80 milliseconds after the J point.
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Dipyridamole-exercise coupled with thallium-201
single photon emission tomography (SPECT)
The test started with dipyridamole infusion (0.8 mg/kg
body weight for four minutes) as the patient performed
a symptom-limited ergometer bicycle exercise test using
standard protocol with permanent monitoring by a 12-
lead ECG. At near-maximal exercise, 92 MBq of thallium-
201 was injected intravenously. The initial images (stress)
were obtained five minutes after the injection. The my-
ocardial uptake of thallium was assessed in 32 projec-
tions with a 180-degree tomographic acquisition gamma
camera. Late redistribution imaging four hours after
stress test was obtained at rest after another injection
of thallium-201, 37 MBq, through the same technique.
For the images, background noise was automatically sub-
tracted, and they were filtered in back position without
attenuation correction. Sagittal, coronal, and transverse
sections were obtained after reconstruction, and were re-
oriented to the three standard cardiac planes for visual
interpretation. Each left ventricle segment was classified
visually as normal or abnormal (transient or persistent
defect). The two physicians involved in the interpretation
were unaware of any clinical information regarding the
patients. Differences in interpretation between observers
were resolved by consensus. Patients were assigned to
three groups: (1) normal images; (2) transient defects,
that is patients with partial or total normalization (redis-
tribution) in all initially abnormal myocardial segments;
and (3) persistent defects, that is, patients with no redis-
tribution in any initially abnormal myocardial segments.
Dobutamine stress echocardiography (DSE)
DSE was performed in a standard fashion. A complete
echocardiographic examination was first performed, and
left ventricular wall motion was analyzed. Dobutamine
infusion was begun after the baseline study at 5 lg/kg/min,
and then at 10, 20, 30, and up to 40 lg/kg/min, using three-
minute increments. Blood pressure and ECG tracing
were monitored during dobutamine infusion. A dobu-
tamine test was considered positive if a new wall motion
abnormality was detected during dobutamine infusion.
Short-acting beta-blocker (Esmolol) was used at the end
of the test.
Coronary angiography
Opacification was performed with standard 5F Judkins
(Cordis, Issy-les-Roulineaux, France) diagnostic catheter
and injection of standard nonionic contrast media. Nitro-
glycerine (400 lg) was injected in the coronary before
the series of contrast injections. Images in multiple views
were recorded at a rate of 25 frames/second. Four inci-
dences or more were obtained for the left coronary artery,
and two or more for the right. Computerized algorithms
were used to quantify the diameter of the lesion (QCA;
Philips, Best, The Netherlands). A stenosis was consid-
ered significant if the diameter of the lumen was reduced
≥50% in one incidence on QCA analysis. In RTR with
abnormal scintigram, the coronary artery that fed the
area of the perfusion defect was identified on the basis of
anatomic distribution of the vessels. Each angiogram was
analyzed by two independent operators (J.L.B., G.H.).
Studied parameters and definitions
For each RTR, the following parameters were
recorded: age, sex, weight, body mass index (BMI), pri-
mary renal disease, previous graft, time on dialysis and
on transplantation, serum creatinine, hypertension, dia-
betes, current or past smoking (more than 10 cigarettes/
day for at least 10 years), hypercholesterolemia, hy-
pertriglyceridemia, hyperuricemia, and family history of
CVD. Hypertension was defined (1) as blood pressure
>140/90 mm Hg measured at least three times after a
resting period of 10 minutes in a lying position (Joint
National Committee VII criteria), or (2) as a need for
antihypertensive drugs. Diabetes was defined as a fast-
ing glycemia >7 mmol/L. Hypercholesterolemia was de-
fined as total cholesterol when fasting >6 mmol/L or
low-density lipoprotein (LDL) cholesterol >4.9 mmol/L
(or as a need for cholesterol-lowering drugs), and hyper-
triglyceridemia was defined as triglycerides when fasting
>2 mmol/L. Overweight was defined as a BMI >25 kg/
m2. Hyperuricemia was defined as uric acid when fasting
>550 lmol/L (or as a need for uric acid-lowering drugs).
Previous CVD was recorded: coronary artery disease,
left ventricular hypertrophy (LVH), aortic aneurysm and
atheroma, ischemic stroke, and lower limb vascular dis-
ease. LVH was echocardiographically defined as a ven-
tricular mass greater than 163 g/m2 in men and 121 g/m2
in women. The main treatments were also consid-
ered: angiotensin-converting enzyme (ACE) inhibitors,
beta-blockers, calcium antagonist, diuretics, statins, and
insulin.
During the follow-up, major adverse cardiac events
(MACE) were defined as the occurrence of sudden death,
myocardial infarction, need for coronary revasculariza-
tion, or angioplasty. Other vascular events, mainly is-
chemic strokes, were also recorded.
Statistical analysis
The statistical software was SAS version 6.11 (Cary,
NC, USA). Statistiscal analysis was performed by analysis
of variance (ANOVA) and Student t test for continuous
data, and the chi-square test or Fisher exact test for fre-
quency analysis. Time-to-event analysis was performed
using the Kaplan-Meier method, with comparison be-
tween event-free survival curves made by the log-rank
test.
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A regression logistic model was used to identify cor-
relates of IMI. Factors included in the model were those
obtained after comparison between groups of all the vari-
ables in univariate analysis with P less than 0.25. The
variables tested were age, sex, time on dialysis, acute
rejection, hypertension, hyperuricemia, LVH, choles-
terolemia, serum creatinine, and calcium antagonist and
beta-blocker treatment.
A Cox proportional hazards regression model was cre-
ated to identify factors associated with the occurrence
of cardiovascular events. Factors included in the model
were those obtained after comparison between groups of
all the variables in univariate analysis with P less than
0.25. The variables tested were age, sex, time on dialysis,
time on transplantation, acute rejection, family history of
CVD, diabetes, hypertension, cigarette smoking, dyslipi-
demia, cholesterolemia, BMI, IMI, and calcium antago-
nist treatment.
The significance threshold was P < 0.05.
RESULTS
Population characteristics
The characteristics of the patients are shown in
Table 1. Most were men; the mean age of the popula-
tion was 58 years. Mean time on dialysis and on trans-
plantation was 41 months and 62 months, respectively.
Twenty-six patients (27%) experienced at least one acute
rejection at the time of the evaluation. Most patients were
treated by steroids and anticalcineurin agents.
A majority of patients had cardiovascular risk factors.
No patients had symptoms suggestive of angina at the
time of the evaluation. Resting ECG did not show marked
ST abnormalities.
Prevalence of inducible myocardial ischemia
All the patients had an exercise test. Four were positive
for ischemia, showing ST-segment depression in three,
and ventricular arrythmias in one. All the patients had
a SPECT coupled with dipyridamole. SPECT scan was
abnormal in 11 patients, showing transient defect of per-
fusion. Dobutamine stress echocardiography was per-
formed in 79 patients (81%). It was interrupted due to
ventricular arrythmias in one patient, and a wall motion
abnormality was observed in three cases (Table 2). On
the whole, 12 patients (12%) had at least one abnormal
test and were considered as having IMI (IMI group).
Prevalence of coronary stenosis
The 12 patients with IMI had coronary angiography
(Table 2). Nine presented abnormalities on angiogram,
but a ≥50% stenosis was observed in only five cases
(42%). Thus, IMI was not related to a significant lesion in
Table 1. Characteristics of the study population
Characteristics
Mean ± SD (min-max) or
Number of patients (%) N = 97
Age years 58 ± 6 (50–73)
Sex (male/female) 64/33
BMI 25.7 ± 5.5 (20–39)
Initial nephropathy
Chronic glomerulonephritis 42
Chronic interstitial nephritis 12
Nephroangiosclerosis 18
Diabetes 3
Polycystic kidney disease 20
Other 1
Unknown 1
Time on dialysis months 41 ± 44 (1–249)
Time on transplantation months 62 ± 40 (1–108)
Acute rejection (number of patient) 26 (27%)
Acute rejection (number by patient) 0.34/patient
Serum creatinine lmol/L 134 ± 42 (70–297)
Steroids % 95 (98%)
Anticalcineurin agents % 93 (96%)
Diabetes % 16 (17%)
Hypertension % 91 (94%)
Dyslipidemia % 75 (77%)
Cholesterolemia mmol/L 5.8 ± 0.9 (2.4–8.5)
Triglyceridemia mmol/L 1.7 ± 0.8 (0.7–4.5)
Hyperuricemia 68 (70%)
Uricemia lmol/L 445 ± 94 (235–622)
Family history of cardiovascular disease % 5 (5%)
History of smoking or current smoker % 46 (47%)
BMI >25 kg/m2 % 43 (44%)
Previous coronary artery disease % 10 (10%)
Left ventricular hypertrophy % 63 (65%)
Previous aortic aneurysm 3 (3%)
Previous ischemic stroke % 6 (6%)
Previous lower limb vascular disease % 13 (13%)
Statin % 72 (74%)
ACE inhibitor % 43 (44%)
Beta-blockers % 43 (44%)
Diuretics % 36 (37%)
Calcium antagonist % 46 (47%)
Insulin 14 (14.5%)
seven cases. None of the 12 patients referred to coronary
angiography underwent coronary revascularization.
Correlates of IMI
The results of the multivariate analysis are shown in
Table 3. Acute rejection, LVH, and calcium antagonists
were the only correlates of IMI (calcium antagonists be-
ing protective against IMI).
Predictive factors for major cardiovascular events
All the patients had been followed-up for four years.
During the observation time, three patients died from
noncardiac cause (one of gastric neoplasia, one of lung
neoplasia, one of pneumonia), and two lost their graft
because of chronic rejection. Kaplan-Meier event-free
survival curves showed a significant increase in major car-
diovascular events in the IMI group (P = 0.0001, Fig. 2).
The IMI group had higher four-year incidence of MACE
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Table 2. Results of the tests for detecting IMI and of coronary angiography
Patient Sex Age Exercise test SPECT scan Stress echocardiography Coronary angiography
1 M 51 Nondiagnostic Positive inferior Not performed Occlusion right coronary artery
2 M 54 Normal Positive inferior-apical Normal Diffuse narrowing Nonsignificant
stenosis of right coronary artery
3 M 63 Normal Positive inferior-septal Nondiagnostic Diffuse narrowing
4 M 51 Positive ventricular Positive inferior Nondiagnostic ventricular Normal
arrythmias arrythmias
5 M 65 Nondiagnostic Positive inferior Not performed Stenosis right coronary artery
6 M 63 Positive Positive inferior, Normal Stenosis left anterior descending
lateral, apical and right coronary artery
7 M 56 Positive Normal Positive apical Normal
8 M 63 Nondiagnostic Positive inferior Positive all segments Normal
9 F 59 Positive Positive lateral Normal Diffuse narrowing
10 M 65 Nondiagnostic Positive inferior-septal Normal Diffuse narrowing
11 F 62 Normal Positive anterior Normal Occlusion diagonale branch
12 M 54 Normal Positive inferior defect Positive inferior-apical Stenosis right coronary artery
Table 3. Multivariate analysis of correlates of IMI
Variables Odds ratio 95% CI P value
Acute rejection 11.4 1.4–95.5 0.025
Left ventricular hypertrophy 17.6 1.4–223.1 0.027
Calcium antagonist treatment 0.09 0.01–0.7 0.022
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Fig. 2. Survival free of major cardiovascular events in the IMI+ and
in the IMI− populations.
(42% vs. 8%), sudden death (25% vs. 1.2%), and non-
fatal myocardial infarction or coronary revasculariza-
tion (17% vs. 7%) and ischemic stroke (8% vs. 1.2%)
(Table 4). In this group, a MACE was observed in four of
the five patients with coronary stenosis, and in one patient
with normal angiography. The Cox proportional hazards
regression model revealed that only diabetes mellitus and
IMI had an independent significant effect on major car-
diovascular events (Table 5).
Table 4. Four-year incidence of major cardiovascular events in the
IMI+ and in the IMI− populations
Myocardial
Death infarction
cardiac or coronary Ischemic
MACE origin revascularization stroke
IMI+ (N = 12) 5 (42%) 3 (25%) 2 (17%) 1 (8%)
IMI– (N = 85) 7 (8%) 1 (1.2%) 6 (7%) 1 (1.2%)
MACE, major adverse cardiac events.
DISCUSSION
We found a 12.4% prevalence of IMI, silent in all cases,
in our population of renal transplant recipients (RTR).
IMI was investigated in only two previous studies: in
one, the prevalence was 18%, but patients were either
hemodialyzed or transplanted [16]. In the second study,
performed only among RTR, Derfler et al [25] found a
39% prevalence of IMI. These two studies were small,
with only 42 and 23 RTR, respectively. The study of Der-
fler et al is the only one we can compare our results with;
our IMI prevalence was four times lower.
This relatively low prevalence of IMI was unexpected
because the patients had numerous risk factors of coro-
nary artery disease. Multiple factors may explain this low
prevalence. The first factor is the low incidence of coro-
nary artery disease among our dialysis patients. In fact,
only 10% of our RTR had a previous history of coro-
nary artery disease. The second factor is the low num-
ber of diabetic patients in our population. At the time of
the evaluation, only 17% of the studied population was
diabetic. In the United States, post-transplant diabetes
mellitus occurred in more than 25% of the transplant pop-
ulation in the first three years after transplantation [26,
27]. The third factor is our policy of very active treatments
of all the treatable risk factors for cardiovascular disease.
The large use of ACE inhibitors and statins may also play
a role because these drugs are known to decrease the
incidence of cardiovascular events in high-risk patients
[28, 29]. Furthermore, we selected dialyzed patients for
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Table 5. Cox model of risk factors of major cardiovascular events
Hazards
Variables ratio 95% CI P value
Diabetes 58.2 1.25–2734 0.04
Inducible myocardial ischemia 31.1 1.4–689 0.03
Acute rejection 18.4 0.9–3946 0.06
Calcium antagonist treatment 0.04 0.01–1.02 0.05
transplantation on the basis of recommended criteria
[17]. Only patients older than 65 years of age, type II dia-
betics with lower limb amputation, and patients with ex-
tensive nonrevascularizable cononary artery disease are
judged not suitable for transplantation, thus there is no
bias in selection. It is also unlikely that we underestimated
the prevalence of IMI because most of the patients per-
formed two detection tests, and 81% of them underwent
DSE. Finally, as acute rejection was a correlate for IMI,
the low prevalence of IMI could have been explained by
a low prevalence of acute rejection. This was not the case
since we observed a usual rate of acute rejection.
The multivariate analysis evidenced that the only cor-
relates for IMI were acute rejection and LVH. The corre-
lation between acute rejection and IMI is an interesting
finding, but this result should be considered preliminary
because our study is small and the confidence interval is
wide. Two features can explain the increased risk of IMI
in patients with acute rejection. First, the high doses of
steroids given as treatment for acute rejection aggravate
cardiovascular risk factors such as hypertension and dia-
betes. Second, the inflammatory process triggered by the
immunologic reaction is associated with cardiovascular
events [5]. This study also strengthens the relationships
between LVH and myocardial ischemia [30].
Another result of this study is that IMI had a strong ef-
fect on the occurrence of MACE and of ischemic stroke.
More than 40% of the patients in the IMI group had a
cardiovascular event, and 25% died because of cardiac
causes. Furthermore, this result was obtained after a rel-
atively short follow-up.
What are our study limitations? One limitation of
the methods for detecting stress-induced myocardial is-
chemia is the dependence of these methods on flow-
limiting coronary stenosis. In this study, five patients had
significant coronary stenosis, and four had coronary nar-
rowing. In the latter, IMI might be due to resistance to
blood flow resulting from diffuse atherosclerosis and en-
dothelial dysfunction. We studied only RTR ≥50 years of
age. We chose this age limit because it was not possible
to look for IMI in the whole population of RTR, and age
is a major risk factor for cardiovascular events.
CONCLUSION
In RTR aged ≥50 years, acute rejection and LVH were
correlates of IMI. IMI and diabetes mellitus were associ-
ated with MACE and ischemic stroke. Regular screenings
of IMI may be useful to select patients who need intensive
reduction of cardiovascular risk factors.
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